Imaging and oncologic drug development

Journal of Clinical Oncology

Volumn 24, Issue 20, 2006, Pages 3261-3273

  El Deiry, Wafik S ^a   Sigman, Caroline C ^a   Kelloff, Gary J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; ERLOTINIB; FLAVOPIRIDOL; FLUORODEOXYGLUCOSE F 18; GEFITINIB; ROSCOVITINE; SORAFENIB;

CLINICAL ASSESSMENT; CLINICAL TRIAL; COLON CANCER; DRUG DEVELOPMENT; DRUG MECHANISM; DRUG SCREENING; DRUG TARGETING; HUMAN; ISOTOPE LABELING; KIDNEY CANCER; LUNG NON SMALL CELL CANCER; MOLECULAR IMAGING; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; REVIEW; DRUG APPROVAL; ECHOGRAPHY; FOOD AND DRUG ADMINISTRATION; HEALTH CARE ORGANIZATION; NEOPLASM; OPTICS; POSITRON EMISSION TOMOGRAPHY; RADIOGRAPHY; SCINTISCANNING; TREATMENT OUTCOME; UNITED STATES;

DRUG APPROVAL; DRUG EVALUATION; HUMANS; NATIONAL INSTITUTES OF HEALTH (U.S.); NEOPLASMS; OPTICS; POSITRON-EMISSION TOMOGRAPHY; TREATMENT OUTCOME; ULTRASONOGRAPHY; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 33745963467     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.06.5623     Document Type: Review

References (118)

1. Welch HG, Schwartz LM, Woloshin S: Are increasing 5-year survival rates evidence of success against cancer? JAMA 283:2975-2978, 2000
2. Travis J: Cancer: Gleevec, chapter two-New leukemia drug aims to overcome resistance. Science 305:319-321, 2004
3. Shah NP, Tran C, Lee FY, et al: Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305:399-401, 2004
4. Kwak EL, Sordella R, Bell DW, etal: Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci U S A 102:7665-7670, 2005
5. Nagata Y, Lan KH, Zhou X, et al: PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6:117-127, 2004
6. Kelloff GJ, Hoffman JM, Johnson B, et al: Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res 11:2785-2808, 2005
7. Kelloff GJ, Krohn KA, Larson SM, et al: The progress and promise of molecular imaging probes in oncologic drug development. Clin Cancer Res 11:7967-7985, 2005
8. Czernin J, Weber WA, Herschman HR: Molecular imaging in the development of cancer therapeutics. Annu Rev Med 57:99-118, 2006
9. Ricci MS, El-Deiry WS: Novel strategies for therapeutic design in molecular oncology using gene expression profiles. Curr Opin Mol Ther 2:682-690, 2000
10. Misek DE, Imafuku Y, Hanash SM: Application of proteomic technologies to tumor analysis. Pharmacogenomics 5:1129-1137, 2004
11. Tian X, Chakrabarti A, Amirkhanov NV, et al: External imaging of CCND1, MYC, and KRAS oncogene mRNAs with tumor-targeted radionuclide-PNA-Peptide Chimeras. Ann N Y Acad Sci 1059:106-144, 2005
12. Reilly RM, Kiarash R, Sandhu J, et al: A comparison of EGF and MAb 528 labeled with 111In for imaging human breast cancer. J Nucl Med 41: 903-911, 2000
13. Hammond LA, Cavanaugh SX, Thomas CR: An image worth a thousand lives? Nat Biotechnol 22:677-678, 2004
14. Blankenberg FG, Mandl S, Cao YA, et al: Tumor imaging using a standardized radiolabeled adapter protein docked to vascular endothelial growth factor. J Nucl Med 45:1373-1380, 2004
15. Shaharabany M, Abramovitch R, Kushnir T, et al: In vivo molecular imaging of met tyrosine kinase growth factor receptor activity in normal organs and breast tumors. Cancer Res 61:4873-4878, 2001
16. Shults MD, Imperiali B: Versatile fluorescence probes of protein kinase activity. J Am Chem Soc 125:14248-14249, 2003
17. Vazquez ME, Nitz M, Stehn J, et al: Fluorescent caged phosphoserine peptides as probes to investigate phosphorylation-dependent protein associations. J Am Chem Soc 125:10150-10151, 2003
18. Wang W, Ho WC, Dicker DT, et al: Acridine derivatives activate p53 and induce tumor cell death through BAX. Cancer Biol Ther 4:893-898, 2005
19. Wang S, El-Deiry WS: Inducible silencing of KILLER/DR5 in vivo promotes bioluminescent colon tumor xenograft growth and confers resistance to chemotherapeutic agent 5-fluorauracil. Cancer Res 64:6666-6672, 2004
20. Wang W, El-Deiry WS: Bioluminescent molecular imaging of endogenous and exogenous p53-mediated transcription in vitro and in vivo using an HCT116 human colon carcinoma xenograft model. Cancer Biol Ther 2:196-202, 2003
21. Wang S, El-Deiry WS: Requirement of p53 targets in chemosensitization of colonic carcinoma to death ligand therapy. Proc Natl Acad Sci U S A 100:15095-15100, 2003
22. Iyer M, Salazar FB, Lewis X, et al: Non-invasive imaging of a transgenic mouse model using a prostate-specific two-step transcriptional amplification strategy. Transgenic Res 14:47-55, 2005
23. De A, Gambhir SS: Noninvasive imaging of protein-protein interactions from live cells and living subjects using bioluminescence resonance energy transfer. FASEB J 19:2017-2019, 2005
24. Paulmurugan R, Gambhir SS: Novel fusion protein approach for efficient high-throughput screening of small molecule-mediating protein-protein interactions in cells and living animals. Cancer Res 65:7413-7420, 2005
25. Safran M, Kim WY, O'Connell F, et al: Mouse model for noninvasive imaging of HIF prolyl hydroxylase activity: Assessment of an oral agent that stimulates erythropoietin production. Proc Natl Acad Sci U S A 103:105-110, 2006
26. Lavely WC, Scarfone C, Cevikalp H, et al: Phantom validation of coregistration of PET and CT for image-guided radiotherapy. Med Phys 31:1083-1092, 2004
27. Piron CA, Causer P, Jong R, et al: A hybrid breast biopsy system combining ultrasound and MRI. IEEE Trans Med Imaging 22:1100-1110, 2003
28. Borgwardt L, Hojgaard L, Carstensen H, et al: Increased fluorine-18 2-fluoro-2-deoxy-D-glucose (FDG) uptake in childhood CNS tumors is correlated with malignancy grade: A study with FDG positron emission tomography/magnetic resonance imaging coregistration and image fusion. J Clin Oncol 23: 3030-3037, 2005
29. Sodee DB, Faulhaber PF, Nelson AD, et al: The prognostic significance of indium-111-capromab penetide. J Clin Oncol 22:379-381, 2004
30. Goerres GW, Kamel E, Seifert B, et al: Accuracy of image coregistration of pulmonary lesions in patients with non-small cell lung cancer using an integrated PET/CT system. J Nucl Med 43:1469-1475, 2002
31. Jaffer FA, Weissleder R: Molecular imaging in the clinical arena. JAMA 293:855-862, 2005
32. Shields AF: PET imaging with 18F-FLT and thymidine analogs: Promise and pitfalls. J Nucl Med 44:1432-1434, 2003
33. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 100:57-70, 2000
34. Vogelstein B, Kinzler KW: Cancer genes and the pathways they control. Nat Med 10:789-799, 2004
35. Fearon ER: Human cancer syndromes: Clues to the origin and nature of cancer. Science 278: 1043-1050, 1997
36. Karin M, Greten FR: NF-kappaB: Linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 5:749-759, 2005
37. Mitin N, Rossman KL, Der CJ: Signaling interplay in Ras superfamily function. Curr Biol 15: R563-R574, 2005
38. Hennessy BT, Smith DL, Ram PT, et al: Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 4:988-1004, 2005
39. Sieber OM, Heinimann K, Tomlinson IP: Genomic instability: The engine of tumorigenesis? Nat Rev Cancer 3:701-708, 2003
40. Wang Z, Cummins JM, Shen D, et al: Three classes of genes mutated in colorectal cancers with chromosomal instability. Cancer Res 64:2998-3001, 2004
41. Rajagopalan H, Jallepalli PV, Rago C, et al: Inactivation of hCDC4 can cause chromosomal instability. Nature 428:77-81, 2004
42. Liu B, Nicolaides NC, Markowitz S, et al: Mismatch repair gene defects in sporadic colorectal cancers with microsatellite instability. Nat Genet 9:48-55, 1995
43. Fearon ER, Vogelstein B: A genetic model for colorectal tumorigenesis. Cell 61:759-767, 1990
44. Bardelli A, Saha S, Sager JA, et al: PRL-3 expression in metastatic cancers. Clin Cancer Res 9:5607-5615, 2003
45. Saha S, Bardelli A, Buckhaults P, et al: A phosphatase associated with metastasis of colorectal cancer. Science 294:1343-1346, 2001
46. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342, 2004
47. El-Deiry WS, Tokino T, Waldman T, et al: Topological control of p21WAF1/CIP1 expression in normal and neoplastic tissues. Cancer Res 55:2910-2919, 1995
48. Castellone MD, Teramoto H, Williams BO, et al: Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis. Science 310:1504-1510, 2005
49. Markowitz S, Wang J, Myeroff L, et al: Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science 268:1336-1338, 1995
50. Jansson A, Sun XF: Bax expression decreases significantly from primary tumor to metastasis in colorectal cancer. J Clin Oncol 20:811-816, 2002
51. Eliazer S, Spencer J, Ye D, et al: Alteration of mesodermal cell differentiation by EWS/FLI-1, the oncogene implicated in Ewing's sarcoma. Mol Cell Biol 23:482-492, 2003
52. Wong S, Witte ON: The BCR-ABL story: Bench to bedside and back. Annu Rev Immunol 22:247-306, 2004
53. Leslie NR, Downes CP: PTEN function: How normal cells control it and tumour cells lose it. Biochem J 382:1-11, 2004
54. Zhou BP, Liao Y, Xia W, et al: Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells. Nat Cell Biol 3:245-252, 2001
55. Okano J, Gaslightwala I, Bimbaum MJ, et al: Akt/protein kinase B isoforms are differentially regulated by epidermal growth factor stimulation. J Biol Chem 275:30934-30942, 2000
56. Moscatello DK, Holgado-Madruga M, Godwin AK, et al: Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res 55:5536-5539, 1995
57. Castillo L, Etienne-Grimaldi MC, Fischel JL, et al: Pharmacological background of EGFR targeting. Ann Oncol 15:1007-1012, 2004
58. Cappuzzo F, Hirsch FR, Rossi E, et al: Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 97:643-655, 2005
59. Vogelzang NJ: Treatment options in metastatic renal carcinoma: An embarrassment of riches. J Clin Oncol 24:1-3, 2006
60. Hahn SM, Bernhard EJ, Regine W, et al: A phase I trial of the farnesyltransferase inhibitor L-778,123 and radiotherapy for locally advanced lung and head and neck cancer. Clin Cancer Res 8:1065-1072, 2002
61. Markowitz S: DNA repair defects inactivate tumor suppressor genes and induce hereditary and sporadic colon cancers. J Clin Oncol 18.75S-80S, 2000
62. Bootsma D, Kraemer KH, Cleaver J, et al: Nucleotide excision repair syndromes: xeroderma pigmentosum, Cockayne syndrome and trichothiodystrophy, in Vogelstein B, Kinzler KW (eds): The Genetic Basis of Human Cancer. New York, NY, McGraw-Hill, 1998, pp 245-274
63. Powell SN, Kachnic LA: Roles of BRCA1 and BRCA2 in homologous recombination, DNA replication fidelity and the cellular response to ionizing radiation. Oncogene 22:5784-5791, 2003
64. Howlett NG, Taniguchi T, Olson S, et al: Biallelic inactivation of BRCA2 in Fanconi anemia. Science 297:606-609, 2002
65. van der Heijden MS, Brody JR, Dezentje DA, et al: In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor. Clin Cancer Res 11:7508-7515, 2005
66. Thayer SP, di Magliano MP, Heiser PW, et al: Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature 425:851-856, 2003
67. Bryant HE, Schultz N, Thomas HD, et al: Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434:913-917, 2005
68. Fei P, El-Deiry WS: P53 and radiation responses. Oncogene 22:5774-5783, 2003
69. Orlowski RZ, Baldwin AS Jr: NF-kappaB as, a therapeutic target in cancer. Trends Mol Med 8:385-389, 2002
70. Hideshima T, Bergsagel PL, Kuehl WM, et al: Advances in biology of multiple myeloma: Clinical applications. Blood 104:607-618, 2004
71. Moeller BJ, Dreher MR, Rabbani ZN, et al: Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity. Cancer Cell 8:99-110, 2005
72. Rosato RR, Grant S: Histone deacetylase inhibitors in cancer therapy. Cancer Biol Ther 2:30-37, 2003
73. Calin GA, Dumitru CD, Shimizu M, et al: Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 99:15524-15529, 2002
74. Parr MJ, Manome Y, Tanaka T, et al: Tumor-selective transgene expression in vivo mediated by an E2F-responsive adenoviral vector. Nat Med 3:1145-1149, 1997
75. Shih JY, Tsai MF, Chang TH, et al: Transcription repressor slug promotes carcinoma invasion and predicts outcome of patients with lung adenocarcinoma. Clin Cancer Res 11:8070-8078, 2005
76. Hidalgo M, Eckhardt SG: Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst 93:178-193, 2001
77. Liu JJ, Wang W, Dicker DT, et al: Bioluminescent imaging of TRAIL-induced apoptosis through detection of caspase activation following cleavage of DEVD-aminoluciferin. Cancer Biol Ther 4:885-892, 2005
78. Shah K, Tung CH, Breakefield XO, et al: In vivo imaging of S-TRAIL-mediated tumor regression and apoptosis. Mol Ther 11:926-931, 2005
79. Sweeney TJ, Mailander V, Tucker AA, et al: Visualizing the kinetics of tumor-cell clearance in living animals. Proc Natl Acad Sci U S A 96:12044-12049, 1999
80. Contag CH, Bachmann MH: Advances in in vivo bioluminescence imaging of gene expression. Annu Rev Biomed Eng 4:235-260, 2002
81. Chang WC, Everley LC, Pfeiffer GR II, et al: Sulindac sulfone is most effective in modulating beta-catenin-mediated transcription in cells with mutant APC. Ann N Y Acad Sci 1059:41-55, 2005
82. Kung AL, Zabludoff SD, France DS, et al: Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway. Cancer Cell 6:33-43, 2004
83. Massoud TF, Gambhir SS: Molecular imaging in living subjects: Seeing fundamental biological processes in a new light. Genes Dev 17:545-580, 2003
84. Paulmurugan R, Massoud TF, Huang J, et al: Molecular imaging of drug-modulated protein-protein interactions in living subjects. Cancer Res 64:2113-2119, 2004
85. Ray P, De A, Min JJ, et al: Imaging tri-fusion multimodality reporter gene expression in living subjects. Cancer Res 64:1323-1330, 2004
86. Zhang GJ, Safran M, Wei W, et al: Bioluminescent imaging of Cdk2 inhibition in vivo. Nat Med 10:643-648, 2004
87. Dicker DT, Kim SH, Jin Z, et al: Heterogeneity in non-invasive detection of apoptosis among human tumor cell lines using annexin-V tagged with EGFP or Qdot-705. Cancer Biol Ther 4:1014-1017, 2005
88. Marten K, Bremer C, Khazaie K, et al: Detection of dysplastic intestinal adenomas using enzyme-sensing molecular beacons in mice. Gastroenterology 122:406-414, 2002
89. Kelly K, Alencar H, Funovics M, et al: Detection of invasive colon cancer using a novel, targeted, library-derived fluorescent peptide. Cancer Res 64: 6247-6251, 2004
90. Shah R, El-Deiry WS: p53-Dependent activation of a molecular beacon in tumor cells following exposure to doxorubicin chemotherapy. Cancer Biol Ther 3:871-875, 2004
91. Fei P, Wang W, Kim SH, et al: Bnip3L is induced by p53 under hypoxia, and its knockdown promotes tumor growth. Cancer Cell 6:597-609, 2004
92. Li Y, Podsypanina K, Liu X, et al: Deficiency of PTEN accelerates mammary oncogenesis in MMTV-Wnt-1 transgenic mice. BMC Mol Biol 2:2, 2001
93. Xu X, Wagner KU, Larson D, et al: Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation. Nat Genet 22:37-43, 1999
94. Ma X, Ziel-van der Made AC, Autar B, et al: Targeted biallelic inactivation of PTEN in the mouse prostate leads to prostate cancer accompanied by increased epithelial cell proliferation but not by reduced apoptosis. Cancer Res 65:5730-5739, 2005
95. Hingorani SR, Wang L, Multani AS, et al: Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7:469-483, 2005
96. Hingorani SR, Petricoin EF, Maitra A, et al: Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 4:437-450, 2003
97. Olive KP, Tuveson DA, Ruhe ZC, et al: Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 119:847-860, 2004
98. Tuveson DA, Shaw AT, Willis NA, et al: Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell 5:375-387, 2004
99. Johnson L, Mercer K, Greenbaum D, et al: Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature 410:1111-1116, 2001
100. Yu Q, Geng Y, Sicinski P: Specific protection against breast cancers by cyclin D1 ablation. Nature 411:1017-1021, 2001
101. Giuriato S, Rabin K, Fan AC, et al: Conditional animal models: A strategy to define when oncogenes will be effective targets to treat cancer. Semin Cancer Biol 14:3-11, 2004
102. Boxer RB, Jang JW, Sintasath L, et al: Lack of sustained regression of c-MYC-induced mammary adenocarcinomas following brief or prolonged MYC inactivation. Cancer Cell 6:577-586, 2004
103. Arvanitis C, Felsher DW: Conditionally MYC: Insights from novel transgenic models. Cancer Lett 226:95-99, 2005
104. Yu Q, Sicinska E, Geng Y, et al: Requirement for CDK4 kinase function in breast cancer. Cancer Cell 9:23-32, 2006
105. Landis MW, Pawlyk BS, Li T, et al: Cyclin D1-dependent kinase activity in murine development and mammary tumorigenesis. Cancer Cell 9:13-22, 2006
106. Vooijs M, Jonkers J, Lyons S, et al: Noninvasive imaging of spontaneous retinoblastoma pathway-dependent tumors in mice. Cancer Res 62:1862-1867, 2002
107. Shachaf CM, Kopelman AM, Arvanitis C, et al: MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature 431:1112-1117, 2004
108. Sehgal CM, Arger PH, Rowling SE, et al: Quantitative vascularity of breast masses by Doppler imaging: Regional variations and diagnostic implications. J Ultrasound Med 19:427-440, 2000
109. Gee MS, Saunders HM, Lee JC, et al: Doppler ultrasound imaging detects changes in tumor perfusion during antivascular therapy associated with vascular anatomic alterations. Cancer Res 61: 2974-2982, 2001
110. Finnberg N, Kim SH, Furth EE, et al: Noninvasive fluorescence imaging of cell death in fresh human colon epithelia treated with 5-fluorouracil, CPT-11 and/or TRAIL. Cancer Biol Ther 4:937-942, 2005
111. Tromberg BJ, Cerussi A, Shah N, et al: Imaging in breast cancer: Diffuse optics in breast cancer - Detecting tumors in pre-menopausal women and monitoring neoadjuvant chemotherapy. Breast Cancer Res 7:279-285, 2005
112. Tromberg BJ: Optical scanning and breast cancer. Acad Radiol 12:923-924, 2005
113. Jakubowski DB, Cerussi AE, Bevilacqua F, et al: Monitoring neoadjuvant chemotherapy in breast cancer using quantitative diffuse optical spectroscopy: A case study. J Biomed Opt 9:230-238, 2004
114. Cerussi AE, Jakubowski D, Shah N, et al: Spectroscopy enhances the information content of optical mammography. J Biomed Opt 7:60-71, 2002
115. Wang TD, Contag CH, Mandella MJ, et al: Confocal fluorescence microscope with dual-axis architecture and biaxial postobjective scanning. J Biomed Opt 9:735-742, 2004
116. Zhang M, Zhang Z, Blessington D, et al: Pyropheophorbide 2-deoxyglucosamide: A new photosensitizer targeting glucose transporters. Bioconjug Chem 14:709-714, 2003
117. Li H, Marotta D, Kim SK, et al: High payload delivery of optical imaging and photodynamic therapy agents to tumors using phthalocyanine-reconstituted low-density lipoprotein nanoparticles. J Biomed Opt 10:41203, 2005
118. Zheng G, Chen J, Li H, et al: Rerouting lipoprotein nanoparticles to selected alternate receptors for the targeted delivery of cancer diagnostic and therapeutic agents. Proc Natl Acad Sci U S A 102:17757-17762, 2005